Acute Porphyria Drug Database

B01AA07 - Acenocoumarol
Propably not porphyrinogenic
PNP

Rationale
Acenocoumarol is metabolized by CYP 2C9, 1A2 and 2C19, but induction or inhibition of the CYP enzymes are not observed or suspected.
Chemical description
Acenocoumarol is a coumarin derivate.
Therapeutic characteristics
Acenocoumarol is a coumarin derivative and functions as vitamin K antagonist. It is used in the treatment and prevention of thromboembolic diseases. It is administered orally and the elimination half-life from the plasma is from 8 to 11 hours.
Metabolism and pharmacokinetics
Acenocoumarol is metabolized mainly by CYP 2C9, but CYP1A2 and CYP 2C19 are also involved (Thijssen 2000, Ufer 2005). No CYP relevant drug-drug interaction with acenocoumarol as a perpetrator has been reported in the literature (Lexi-Interact, Micromedex, SPC).
IPNet drug reports
Uneventful use reported in 5 patients with acute porphyria.

References

  1. Scientific articles
  2. Thijssen HH, Flinois JP et al. Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes. Drug Metab Dispos. 2000 Nov;28(11):1284-90. PMID 11038154. #4366
  3. Ufer M. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet. 2005;44(12):1227-46. PMID 16372822. #1155
  4. Drug interaction databases
  5. Lexi-Interact, via UpToDate. #1152
  6. Micromedex® 2.0 (online). Drug Interactions). (24.05.2017). #1153
  7. Summary of Product Characteristics
  8. The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC).Sinthrome. #1157

Similar drugs
Explore alternative drugs in similar therapeutic classes B01A / B01AA or go back.

 
© NAPOS 2024
An unhandled error has occurred. Reload 🗙